Table 3

Recommendations for hematopoietic cell transplantation in COVID-19 based on EBMT [11].

Recipients

Scenario	Low-risk disease	High-risk disease
Confirmed diagnosis	Deferred for 3 months	Deferred until asymptomatic and 3 negative PCR tests at least a week apart
Symptoms of URTI	Testing with multiplex respiratory viral PCR, consider deferral	Testing with multiplex respiratory viral PCR, consider deferral
Close contact with COVID-19 patient	PCR test for COVID-19, deferred for 14–21 days	PCR test for COVID-19, deferral based on clinical judgment
Travel to high-risk areas or close contact with a person traveling from high-risk areas	Deferred for 14–21 days	Deferral based on clinical judgment

Donors

Confirmed diagnosis	Excluded from donation	Unclear when can be cleared for future donation
Close contact with COVID-19 patient	Exclude from donation for at least 28 days, monitor closely for symptoms	Follow local guidelines for isolation and testing for COVID-19
Travel to high-risk areas or close contact with person travelling from high-risk areas	Exclude from donation for at least 28 days, monitor closely for symptoms	Follow local guidelines for isolation and testing for COVID-19

Abbreviations: EBMT, European Society for Blood and Marrow Transplantation; PCR, polymerase chain reaction; URTI, upper respiratory tract infection.